497 related articles for article (PubMed ID: 34400714)
1. Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations.
Efrati S; Catalogna M; Abu Hamad R; Hadanny A; Bar-Chaim A; Benveniste-Levkovitz P; Levtzion-Korach O
Sci Rep; 2021 Aug; 11(1):16543. PubMed ID: 34400714
[TBL] [Abstract][Full Text] [Related]
2. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
3. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
5. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
6. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19.
Mazzoni A; Di Lauria N; Maggi L; Salvati L; Vanni A; Capone M; Lamacchia G; Mantengoli E; Spinicci M; Zammarchi L; Kiros ST; Rocca A; Lagi F; Colao MG; Parronchi P; Scaletti C; Turco L; Liotta F; Rossolini GM; Cosmi L; Bartoloni A; Annunziato F;
J Clin Invest; 2021 Jun; 131(12):. PubMed ID: 33939647
[TBL] [Abstract][Full Text] [Related]
7. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.
Jalkanen P; Kolehmainen P; Häkkinen HK; Huttunen M; Tähtinen PA; Lundberg R; Maljanen S; Reinholm A; Tauriainen S; Pakkanen SH; Levonen I; Nousiainen A; Miller T; Välimaa H; Ivaska L; Pasternack A; Naves R; Ritvos O; Österlund P; Kuivanen S; Smura T; Hepojoki J; Vapalahti O; Lempainen J; Kakkola L; Kantele A; Julkunen I
Nat Commun; 2021 Jun; 12(1):3991. PubMed ID: 34183681
[TBL] [Abstract][Full Text] [Related]
10. Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals.
Hirotsu Y; Amemiya K; Sugiura H; Shinohara M; Takatori M; Mochizuki H; Omata M
Front Immunol; 2021; 12():722766. PubMed ID: 34512649
[TBL] [Abstract][Full Text] [Related]
11. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).
Favresse J; Bayart JL; Mullier F; Dogné JM; Closset M; Douxfils J
Clin Microbiol Infect; 2021 Sep; 27(9):1351.e5-1351.e7. PubMed ID: 33975007
[TBL] [Abstract][Full Text] [Related]
12. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.
Callegaro A; Borleri D; Farina C; Napolitano G; Valenti D; Rizzi M; Maggiolo F
J Med Virol; 2021 Jul; 93(7):4612-4615. PubMed ID: 33788281
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals.
Lozano-Ojalvo D; Camara C; Lopez-Granados E; Nozal P; Del Pino-Molina L; Bravo-Gallego LY; Paz-Artal E; Pion M; Correa-Rocha R; Ortiz A; Lopez-Hoyos M; Iribarren ME; Portoles J; Rojo-Portoles MP; Ojeda G; Cervera I; Gonzalez-Perez M; Bodega-Mayor I; Montes-Casado M; Portoles P; Perez-Olmeda M; Oteo J; Sanchez-Tarjuelo R; Pothula V; Schwarz M; Brahmachary M; Tan AT; Le Bert N; Berin C; Bertoletti A; Guccione E; Ochando J
Cell Rep; 2021 Aug; 36(8):109570. PubMed ID: 34390647
[TBL] [Abstract][Full Text] [Related]
15. Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response.
Ontañón J; Blas J; de Cabo C; Santos C; Ruiz-Escribano E; García A; Marín L; Sáez L; Beato JL; Rada R; Navarro L; Sainz de Baranda C; Solera J
EBioMedicine; 2021 Nov; 73():103656. PubMed ID: 34740112
[TBL] [Abstract][Full Text] [Related]
16. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.
Massarweh A; Eliakim-Raz N; Stemmer A; Levy-Barda A; Yust-Katz S; Zer A; Benouaich-Amiel A; Ben-Zvi H; Moskovits N; Brenner B; Bishara J; Yahav D; Tadmor B; Zaks T; Stemmer SM
JAMA Oncol; 2021 Aug; 7(8):1133-1140. PubMed ID: 34047765
[TBL] [Abstract][Full Text] [Related]
18. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine.
Beharier O; Plitman Mayo R; Raz T; Nahum Sacks K; Schreiber L; Suissa-Cohen Y; Chen R; Gomez-Tolub R; Hadar E; Gabbay-Benziv R; Jaffe Moshkovich Y; Biron-Shental T; Shechter-Maor G; Farladansky-Gershnabel S; Yitzhak Sela H; Benyamini-Raischer H; Sela ND; Goldman-Wohl D; Shulman Z; Many A; Barr H; Yagel S; Neeman M; Kovo M
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34014840
[TBL] [Abstract][Full Text] [Related]
19. Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients.
Haskin O; Ashkenazi-Hoffnung L; Ziv N; Borovitz Y; Dagan A; Levi S; Koren G; Hamdani G; Levi-Erez D; Landau D; Alfandary H
Transplantation; 2021 Nov; 105(11):e226-e233. PubMed ID: 34381004
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis.
Tran S; Truong TH; Narendran A
Eur J Cancer; 2021 Dec; 159():259-274. PubMed ID: 34798454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
